Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria—United States, 2019
The DOI matches its Crossref record.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Varied national drug regulators have registered tafenoquine as a single-dose alternative to the standard 14 days daily dosing with primaquine for presumptive anti-relapse therapy (PART) following a diagnosis of P. vivax malaria [32,33].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 16
- CDC. Yellow book 2018: health information for international travel. New York, NY: Oxford University Press; 2017.
- Mace KE, Arguin PM, Lucchi NW, Tan KR. Malaria surveillance—United States, 2016. MMWR Surveill Summ 2019;68(No. SS-5). · DOI
- Hill, 2006, Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I., Am J Trop Med Hyg, 75, 402, 10.4269/ajtmh.2006.75.402 · DOI · Paper page
- Rueangweerayut, 2017, Hemolytic potential of tafenoquine in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PD Mahidol Variant) versus G6PD-normal volunteers., Am J Trop Med Hyg, 97, 702, 10.4269/ajtmh.16-0779 · DOI · Paper page
- Baird, 2018, Tafenoquine for travelers’ malaria: evidence, rationale and recommendations., J Travel Med, 25, 10.1093/jtm/tay110 · DOI
- Shanks, 2001, A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria., Clin Infect Dis, 33, 1968, 10.1086/324081 · DOI · Paper page
- Hale, 2003, A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum., Clin Infect Dis, 36, 541, 10.1086/367542 · doi:10.1086/367542
- Nasveld, 2010, Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects., Antimicrob Agents Chemother, 54, 792, 10.1128/AAC.00354-09 · doi:10.1128/aac.00354-09
- Dow, 2014, A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area., Malar J, 13, 49, 10.1186/1475-2875-13-49 · doi:10.1186/1475-2875-13-49
- McCarthy, 2018, Blood schizonticidal activity and safety of tafenoquine when administered as chemoprophylaxis to healthy, non-immune participants followed by blood stage Plasmodium falciparum challenge: a randomized, double-blinded, placebo-controlled Phase 1b study., Clin Infect Dis, 69, 480, 10.1093/cid/ciy939 · doi:10.1093/cid/ciy939
- Llanos-Cuentas, 2014, Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study., Lancet, 383, 1049, 10.1016/S0140-6736(13)62568-4 · DOI · Paper page
- Llanos-Cuentas, 2019, Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria., N Engl J Med, 380, 229, 10.1056/NEJMoa1802537 · DOI · Paper page
- Lacerda, 2019, Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria (DETECTIVE Phase III)., N Engl J Med, 380, 215, 10.1056/NEJMoa1710775 · DOI · Paper page
- Mueller, 2007, Plasmodium malariae and Plasmodium ovale—the “bashful” malaria parasites., Trends Parasitol, 23, 278, 10.1016/j.pt.2007.04.009 · DOI · Paper page
- Shimizu, 2015, Optimal primaquine use for radical cure of Plasmodium vivax and Plasmodium ovale malaria in Japanese travelers—a retrospective analysis., Travel Med Infect Dis, 13, 235, 10.1016/j.tmaid.2014.11.005 · DOI
- Faucher, 2013, Primaquine for radical cure of Plasmodium vivax and Plasmodium ovale malaria: an observational survey (2008–2010)., J Travel Med, 20, 134, 10.1111/jtm.12009 · doi:10.1111/jtm.12009
Cited by
Satyagraha, A. W., Sadhewa, A., Panggalo, L. V., Subekti, D., Elyazar, I., Soebianto, S., Mahpud, N., Harahap, A. R., & Baird, J. K. (2021) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0009610 · Cited by 12
Metadata
- Authors
- Haston, J. C., Hwang, J., & Tan, K. R.
- Venue
- MMWR. Morbidity and Mortality Weekly Report
- Published
- 2019-11-22
- Volume
- 68
- Issue
- 46
- Pages
- 1062-1068
- ISSN
- 0149-2195
- 1545-861X
- Cited by
- 49
- References
- 0
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria—United States, 2019. https://app.cochat.ai/papers/10.15585/mmwr.mm6846a4
- The paper
- Haston, J. C., Hwang, J., & Tan, K. R. (2019). Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria—United States, 2019. MMWR. Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm6846a4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.